Title
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
Document Type
Article
Peer Reviewed
1
Publication Date
6-1-2011
Journal/Book/Conference Title
Journal of clinical oncology
Volume
29
NLM Title Abbreviation
J Clin Oncol
DOI
10.1200/JCO.2010.32.6397;
PubMed ID
21537039
Abstract
PURPOSE: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We conducted a phase II trial to assess the activity and tolerability of single-agent bevacizumab in recurrent or persistent endometrial cancer (EMC). PATIENTS AND METHODS: Eligible patients had persistent or recurrent EMC after receiving one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of
Keywords
Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Endometrial Neoplasms/drug therapy/metabolism/mortality, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoplasm Recurrence, Local/drug therapy, Salvage Therapy/methods, Vascular Endothelial Growth Factor A/biosynthesis/blood
URL
http://ir.uiowa.edu/obgyn_pubs/37